Allurion gets FDA nod for weight loss balloon

Allurion Technologies (NYSE:ALUR) announced today that the FDA granted premarket approval (PMA) for its Allurion Gastric Balloon System.

The Allurion Gastric Balloon System features the Allurion Smart Capsule to deliver an AI-powered solution for weight loss. The swallowable system requires no surgery, endoscopy or anesthesia. Once swallowed, the balloon fills and remains in the stomach for approximately four months before self-emptying and passing out naturally.

Allurion Technologies designed its system for delivery in a 15-minute office visit. It eliminates the need for surgery, endoscopy or anesthesia. 

Once about four months pass, the patented release valve opens and the capsule passes. Patients can swallow another Smart Capsule two months after the passage of the first.

Sign up for Blog Updates